Daily Endocrinology Research Analysis
Three endocrine studies stand out today: a mechanistic discovery shows that the ECM protein SPOCK2 restrains immature β-cell proliferation via MMP2, enabling marked expansion and function of stem cell–derived β-cells; a gut commensal, Barnesiella intestinihominis, ameliorates hyperglycemia and liver dysfunction through an acetate–HDAC9–FGF21 epigenetic pathway and is promotable by the prebiotic puerarin; and a pooled analysis of three phase 3 RCTs confirms year-long safety of the nonhormonal NK3
Summary
Three endocrine studies stand out today: a mechanistic discovery shows that the ECM protein SPOCK2 restrains immature β-cell proliferation via MMP2, enabling marked expansion and function of stem cell–derived β-cells; a gut commensal, Barnesiella intestinihominis, ameliorates hyperglycemia and liver dysfunction through an acetate–HDAC9–FGF21 epigenetic pathway and is promotable by the prebiotic puerarin; and a pooled analysis of three phase 3 RCTs confirms year-long safety of the nonhormonal NK3R antagonist fezolinetant for menopausal vasomotor symptoms.
Research Themes
- β-cell regeneration and stem-cell–based diabetes therapy
- Microbiome–epigenetic regulation of metabolism (acetate–HDAC9–FGF21 axis)
- Nonhormonal therapy and pharmacovigilance in menopausal endocrinology
Selected Articles
1. Gut Commensal Barnesiella Intestinihominis Ameliorates Hyperglycemia and Liver Metabolic Disorders.
Across two human cohorts, Barnesiella intestinihominis was depleted in T2D. Oral live B. intestinihominis or its metabolite acetate improved hyperglycemia and hepatic metabolic dysfunction in HFD/STZ and db/db mice by increasing FGF21 via HDAC9 inhibition and H3K27 acetylation at the FGF21 promoter. The prebiotic puerarin promoted B. intestinihominis growth and replicated metabolic benefits.
Impact: Identifies a specific commensal and epigenetic mechanism (acetate–HDAC9–FGF21) linking the microbiome to glucose and liver metabolism, and proposes probiotic–prebiotic strategies for T2D.
Clinical Implications: Supports development of B. intestinihominis as a probiotic or puerarin as a prebiotic to augment endogenous FGF21 and improve glycemia and NAFLD-like features; suggests monitoring FGF21 and short-chain fatty acids as pharmacodynamic biomarkers.
Key Findings
- B. intestinihominis abundance is reduced in feces of T2D patients across two independent centers.
- Oral live B. intestinihominis improves hyperglycemia and liver metabolic disorders in HFD/STZ and db/db mice.
- Acetate elevates FGF21 by inhibiting HDAC9 and increasing H3K27 acetylation at the FGF21 promoter.
- Puerarin promotes B. intestinihominis growth and improves metabolic phenotypes in a microbiota-dependent manner.
Methodological Strengths
- Multi-system validation across human cohorts and two diabetic mouse models
- Mechanistic epigenetic dissection linking SCFA to FGF21 via HDAC9 with functional rescue
Limitations
- Human interventional data are lacking; efficacy and safety of live B. intestinihominis in patients remain untested
- Sample sizes and detailed cohort characteristics are not specified in the abstract
Future Directions: Conduct phase 1/2 trials of B. intestinihominis and puerarin in T2D with FGF21/acetate biomarker readouts; define colonization dynamics, dosing, and long-term hepatic and cardiometabolic outcomes.
Recent studies have highlighted the role of the gut microbiota in type 2 diabetes (T2D). Improving gut microbiota dysbiosis can be a potential strategy for the prevention and management of T2D. Here, this work finds that the abundance of Barnesiella intestinihominis is significantly decreased in the fecal of T2D patients from 2-independent centers. Oral treatment of live B. intestinihominis (LBI) considerably ameliorates hyperglycemia and liver metabolic disorders in HFD/STZ-induced T2D models
2. SPOCK2 controls the proliferation and function of immature pancreatic β-cells through MMP2.
SPOCK2 acts as an extracellular matrix brake on immature β-cell proliferation. Loss of SPOCK2 elevates MMP2 and activates β-integrin–FAK–c-JUN signaling, while exogenous MMP2 drives robust short- and long-term expansion of SC-β-cells with enhanced glucose-stimulated insulin secretion in vitro and in vivo. The work outlines a tractable pathway to expand functional SC-β-cells for transplantation.
Impact: Reveals a previously unrecognized ECM–MMP–integrin axis governing immature human β-cell expansion and function, offering a concrete strategy to scale SC-β-cells for diabetes cell therapy.
Clinical Implications: Enables pre-transplant expansion of SC-β-cells through SPOCK2 inhibition/MMP2 activation to improve graft yield and function; suggests careful evaluation of proliferation–maturation balance and off-target matrix remodeling.
Key Findings
- SPOCK2 is identified as an ECM inhibitor of immature β-cell proliferation using bidirectional modulation and scRNA-seq.
- SPOCK2 loss elevates MMP2 expression/activity, activating β-integrin–FAK–c-JUN signaling.
- Exogenous MMP2 induces pronounced short- and long-term expansion of SC-β-cells with improved GSIS in vitro and in vivo.
Methodological Strengths
- Convergent evidence from bidirectional genetic perturbation and single-cell transcriptomics
- Functional validation with protein treatment and in vitro/in vivo assays of β-cell secretion and expansion
Limitations
- Translational safety and durability of MMP2-mediated expansion not yet established in humans
- Potential off-target extracellular matrix remodeling requires careful assessment
Future Directions: Evaluate small-molecule or biologic modulators of the SPOCK2–MMP2–integrin axis, define maturation trajectories post-expansion, and test efficacy/safety in large-animal transplantation models.
Human pluripotent stem cell-derived β-cells (SC-β-cells) represent an alternative cell source for transplantation in diabetic patients. Although mitogens could in theory be used to expand β-cells, adult β-cells very rarely replicate. In contrast, newly formed β-cells, including SC-β-cells, display higher proliferative capacity and distinct transcriptional and functional profiles. Through bidirectional expression modulation and single-cell RNA-seq, we identified SPOCK2, an ECM protein, as an inhibitor of immature β-cel
3. Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.
Across three 52-week, randomized, double-blind studies, fezolinetant showed acceptable safety with mostly mild TEAEs and low discontinuation. Transaminase elevations (1.5–2.3%) were transient and non-severe, with no Hy’s law cases; endometrial outcomes met FDA safety criteria and neoplasm risk was not increased versus placebo.
Impact: Provides comprehensive, year-long safety evidence for a first-in-class nonhormonal NK3R antagonist for menopausal VMS, supporting wider clinical adoption where hormone therapy is unsuitable.
Clinical Implications: Fezolinetant can be considered for moderate–severe VMS with routine monitoring of liver enzymes; endometrial surveillance aligns with standard care, offering a nonhormonal option for women with HRT contraindications.
Key Findings
- Pooled 52-week safety across three phase 3 trials shows mostly mild TEAEs and low discontinuation with fezolinetant.
- Liver transaminase elevations (1.5–2.3%) were transient, asymptomatic, and not consistent with Hy's law.
- Endometrial safety met FDA criteria; exposure-adjusted analyses showed no increased benign or malignant neoplasm risk vs placebo.
Methodological Strengths
- Large pooled dataset from randomized, double-blind, placebo-controlled phase 3 trials with 52-week follow-up
- Predefined TEAEs of special interest with exposure-adjusted analyses
Limitations
- Primarily safety outcomes; efficacy not the focus of this pooled analysis
- Rare adverse events may require even larger post-marketing datasets
Future Directions: Real-world pharmacovigilance to define rare hepatic or endometrial events and subgroup risk, and head-to-head comparisons with hormone therapy for benefit–risk profiling.
INTRODUCTION: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4). METHODS: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies where women (≥ 40 to ≤ 65 years), with moderate to severe VMS (minimum average ≥ 7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or 45 mg. After 12 weeks, those on placebo were re-randomized to fezolinetant 30 mg or 45 mg, while those on fezolinetant continued on their assigned dose for 40 weeks. SKYLIGHT 4 was a placebo-controlled, double-blind, 52-week safety study. Safety was assessed by frequency of treatment-emergent adverse events (TEAEs) and endometrial events. TEAEs of special interest included liver test elevations and endometrial hyperplasia or cancer or disordered proliferative endometrium. RESULTS: Totals of 952 participants receiving placebo, 1100 receiving fezolinetant 45 mg, and 1103 receiving fezolinetant 30 mg took ≥ 1 dose of study medication. TEAEs occurred in 55.3%, 62.9%, and 65.4%, respectively; exposure-adjusted results were consistent with these results. Most frequent TEAEs in fezolinetant-treated participants included upper respiratory tract infection (7.7-8.3%), headache (6.8-8.2%), coronavirus disease 2019 (5.8-6.1%), back pain (3.1-3.7%), arthralgia (2.9-3.2%), diarrhea (2.3-3.2%), urinary tract infection (2.9-3.4%), and insomnia (2.0-3.0%). The incidence of drug-related serious TEAEs and associated treatment withdrawals was low. Elevations in liver transaminases occurred in 1.5-2.3% of fezolinetant-treated participants, were typically asymptomatic and transient, resolved on treatment or discontinuation, with no evidence of severe drug-induced liver injury (Hy's law). Endometrial safety results were well within US Food and Drug Administration criteria. Analysis of benign and non-benign neoplasm controlled for exposure demonstrated no increased risk versus placebo. CONCLUSION: Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. TRIAL REGISTRATION: ClinicalTrials.gov identifiers, NCT04003155, NCT04003142, and NCT04003389. Graphical abstract available for this article.